Arcturus Therapeutics Holdings Inc [ARCT] stock prices are up 3.48% to $6.84 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARCT shares have gain 10.50% over the last week, with a monthly amount drifted -4.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] stock has seen the most recent analyst activity on October 24, 2025, when H.C. Wainwright downgraded its rating to a Neutral but kept the price target unchanged to $12 for it. Previously, Citigroup downgraded its rating to Neutral on October 23, 2025, and kept the price target unchanged to $12. On October 22, 2025, downgrade downgraded it’s rating to Neutral. Scotiabank initiated its recommendation with a Sector Outperform and recommended $32 as its price target on May 28, 2025. BTIG Research started tracking with a Buy rating for this stock on January 28, 2025, and assigned it a price target of $41. In a note dated August 12, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $70 on this stock.
The stock price of Arcturus Therapeutics Holdings Inc [ARCT] has been fluctuating between $5.85 and $24.17 over the past year. Currently, Wall Street analysts expect the stock to reach $54 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $6.84 at the most recent close of the market. An investor can expect a potential return of 689.47% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
The Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] reported sales of 85.14M for trailing twelve months, representing a drop of -63.54%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.85%, Pretax Profit Margin comes in at -0.72%, and Net Profit Margin reading is -0.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.29 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.66 points at the first support level, and at 6.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.00, and for the 2nd resistance point, it is at 7.17.
Ratios To Look Out For
It’s worth pointing out that Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT]’s Current Ratio is 7.86. Further, the Quick Ratio stands at 7.86, while the Cash Ratio is 5.69. Considering the valuation of this stock, the price to sales ratio is 2.28, the price to book ratio is 0.83.
